The outstanding performance also made Pfizer decide
Posted: Wed Jan 08, 2025 3:58 am
To rely on COVID-19 for its livelihood in the future, assuring investors that the COVID-19 vaccine will be administered as regularly as the flu vaccine, becoming a fixed and impressive performance every year.
However, many people who have been vaccinated against COVID-19 before feel that additional injections are useless, and more people are tired of the epidemic; in addition, whether to get vaccinated has become a political war of words, which also affects the willingness to take the vaccine.
According to statistics from the U.S. Centers for Disease Control and Prevention (CDC), only 17% of people over the age of 18 in the United States have received the latest version of the COVID-19 vaccine from each india telegram company. The antiviral drug Paxlovid has also been greatly reduced due to use, and the federal government will also spend hundreds Thousands of medicines returned.
At the beginning of this year, Pfizer estimated that the antiviral oral drug Paxlovid could sell $8 billion and the vaccine $13.5 billion. Now the industry has revised down its vaccine performance in 2023 to US$12.5 billion, and the total performance estimate of vaccines and drugs in 2024 is only US$8 billion.
Moderna's COVID-19 vaccine will sell US$18.4 billion in 2022, but it is expected to only maintain more than US$6 billion this year.
Company documents obtained by The Wall Street Journal revealed that Pfizer has suspended or terminated funding for the development of a second-generation COVID-19 vaccine, the enterobacter C. difficile vaccine.
Now Pfizer said they will launch new products to boost performance, including nine new drugs and vaccines approved this year. They also said that on the 14th they finalized the acquisition of Seagen, a biotechnology company that develops cancer drugs, and that it will bring in $25 billion in new revenue by the end of 2030.
However, many people who have been vaccinated against COVID-19 before feel that additional injections are useless, and more people are tired of the epidemic; in addition, whether to get vaccinated has become a political war of words, which also affects the willingness to take the vaccine.
According to statistics from the U.S. Centers for Disease Control and Prevention (CDC), only 17% of people over the age of 18 in the United States have received the latest version of the COVID-19 vaccine from each india telegram company. The antiviral drug Paxlovid has also been greatly reduced due to use, and the federal government will also spend hundreds Thousands of medicines returned.
At the beginning of this year, Pfizer estimated that the antiviral oral drug Paxlovid could sell $8 billion and the vaccine $13.5 billion. Now the industry has revised down its vaccine performance in 2023 to US$12.5 billion, and the total performance estimate of vaccines and drugs in 2024 is only US$8 billion.
Moderna's COVID-19 vaccine will sell US$18.4 billion in 2022, but it is expected to only maintain more than US$6 billion this year.
Company documents obtained by The Wall Street Journal revealed that Pfizer has suspended or terminated funding for the development of a second-generation COVID-19 vaccine, the enterobacter C. difficile vaccine.
Now Pfizer said they will launch new products to boost performance, including nine new drugs and vaccines approved this year. They also said that on the 14th they finalized the acquisition of Seagen, a biotechnology company that develops cancer drugs, and that it will bring in $25 billion in new revenue by the end of 2030.